The Danish company Reapplix has developed the product LeucoPatch ™ for treatment of severe chronic foot ulcers. The product has in a clinical study conducted at Bispebjerg Hospital Centre for Wound Healing revealed promising results on up to 10 year old wounds. This has resulted in an investment of 7.6 million DKK from SEED Capital.

Patients with diabetes often experience extensive and poorly healing foot ulcers as a consequence of their disease. European studies show that even after a year of treatment, 12% remain in treatment, and more than a fifth has resulted in an amputation. An amputation means longer hospitalization and a strongly reduced quality of life.

Reapplix in collaboration with Centre for Wound Healing at Bispebjerg Hospital, conducted a clinical study of the treatment of highly chronic wounds with LeucoPatch ™.Thirteen out of sixteen patients with chronic ulcers (including 5 diabetics) experienced a complete healing or a clinically significant effect by using LeucoPatch ™ in the initial study. All cases were severe chronic wounds, which the patients had for up to 10 years.

"In Denmark we use in total nearly three billion DKK annually on wound care, and amputations can easily cost up to one million DKK per patient," says Chariman of the Reapplix board Bo Jesper Hansen and continues: "In Denmark alone we amputated more than 1,000 limbs as a result of severe chronic diabetic foot ulcers. We are therefore convinced that if we continue to show results as in the first clinical study LeucoPatch™ wil help a great many patients with chronic wounds and result in significant savings for the healthcare industry".

Given the impressive clinical results Reapplix have received capital from venture fund SEED Capital. The money will be used to conduct additional clinical efficacy studies of LeucoPatch ™ on diabetic foot ulcers and prepare for commercialization of the product. The potential for LeucoPatch ™ is large with a global market for advanced wound care at over 40 billion DKK.

"We have followed Reapplix via our innovation environment DTU Symbion Innovation for two years and am impressed with both the results they have achieved and the success with which they have handled the challenges any startup business meetings," says Managing Partner at SEED Capital Ulla Brockenhuus Schack.

Reapplix is the first investment from the newly raised SEED Capital Denmark II. LeucoPatch™ is a biological patch. By using the patient's own blood Reapplix creates a totally organic product containing immune cells and growth factors from the patient himself. LeucoPatch™ is in spite of its complex biological content easy and quick to produce - an important product characteristic in the wound care sprecialist's often busy schedules. By adding LeucoPatch ™ to an open and poorly healing wound it will stimulate the cell's healing abilities, and also perform immune cells as an antibacterial layer that can fight and prevent infections and promote wound healing.

Reapplix formed in 2008 by Professor Niels Erik Holm and M.Sc. Rasmus Lundquist received initial funding from the innovation environment DTU Symbion Innovation for further development and testing of their LeucoPatch™ and gained participation in 2009 in the entrepreneurial program Symbion Accelerace - a program that has supported with business development of Reapplix and a loan.

SEED Capital is the largest venture fund in Denmark within the pre-seed and seed segment and specializes in identifying and developing new and innovative technology companies. SEED Capital manages both private and public venture capital funds through innovation environment DTU Symbion Innovation. Public funding allows SEED to invest in start-ups in the early stages, and private funds are invested in the most successful companies in subsequent rounds of investment. SEED manages today approx. 1,5 billion DKK and has about 70 companies in its portfolio.